SCHEMBL21676346

SCHEMBL21676346

CC(C)C1(CC#N)COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20782293 0.84
SCHEMBL9918265 0.78
SCHEMBL9918185 0.74 CYP1A2 (0.30)
SCHEMBL9918266 0.74 CYP1A2 (0.30)
SCHEMBL15944144 0.73
SCHEMBL9918261 0.73 ALDH1A1 (0.31)
SCHEMBL9918264 0.73 ALDH1A1 (0.31)
SCHEMBL17276922 0.71
SCHEMBL17276921 0.71
SCHEMBL9918180 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947254-B2 Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-16 US disclosed
US-20200040010-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-02-06 US disclosed